By Sheeba M. | April 13, 2026

Cannabis Earnings Season: 3 Names That Beat — and 2 That Cracked Under Pressure

TL;DR: Tilray (TLRY) and Organigram (OGI) delivered beat-and-raise quarters, while smaller operators continue to miss on cash flow targets. MSO debt ratios are the key metric to watch through mid-year.

Cannabis earnings season is in full swing, and the divergence between winners and losers is becoming impossible to ignore. While the industry’s narrative has long focused on revenue growth, the real story emerging from Q1 2026 reports is cash flow discipline — and who’s mastered it versus who’s drowning in it.

The Winners

Tilray (TLRY) surprised markets with a 12% beat on adjusted EBITDA — the first time in eight quarters they’ve exceeded analyst consensus. Management cited operational restructuring in Germany and craft beverage segment growth as tailwinds. The stock responded with a 9% single-day gain, its best single-day move since early 2024.

Organigram (OGI) also impressed, reporting positive free cash flow for the second consecutive quarter. Their focus on high-margin white label and API supply contracts — rather than chasing retail expansion — is paying off. Canadian recreational revenue grew 8% sequentially.

The Laggards

Not every story is rosy. Two mid-tier operators reported cash burn rates that spooked analysts. One unnamed operator — later identified as a sub-$200M market cap company — posted a cash burn of $18M against only $14M in quarterly revenue. That’s a runway problem.

C21 Biosciences (CXXA) missed on both top and bottom line, citing slower-than-expected patient acquisition in newly launched markets. While their license portfolio remains valuable, execution risk is real.

What to Watch Next

The key metric for cannabis operators in 2026 isn’t revenue — it’s net debt/EBITDA. Companies that bring that ratio below 3x will be acquisition targets. Those above 6x will face tough choices: raise dilutive capital, sell assets, or risk covenant breaches.

Green Thumb (GTBIF) and Curaleaf (CURA) both guided to net debt/EBITDA below 4x by year-end — watch for those numbers in upcoming quarters.

For investors: Q2 guidance and updated full-year outlooks will be the real arbiter. A company that raises guidance in May could run 20%+ into summer. One that cuts will get punished — hard.

Sources

Track cannabis stocks with the Weedstock Real-Time Tracker

Leave a Reply

📅 Yesterday's News & Older Articles →